IgG antinuclear antibodies (ANAs) are elevated in patients with systemic lupus erythematosus (SLE) compared with patients with discoid lupus erythematosus (DLE). To provide an expanded immunologic view of circulating ANAs in lupus patients, we compared the expressions of IgG, IgM, and IgA ANAs in DLE and SLE patients. In this cross-sectional study, sera from age-, gender-, and ethnic-matched SLE ( = 35), DLE ( = 23), and normal patients ( = 22) were tested for IgG, IgM, and IgA ANAs using enzyme-linked immunosorbent assays (ELISAs) and indirect immunofluorescence (IIF) with monkey esophagus as substrate. ELISAs showed elevated levels of IgG ANA, IgM ANA, and IgG/IgM ANA ratios in SLE patients compared with DLE and normal patients. IgA ANA expression was higher in SLE and DLE patients versus normal patients. IIF studies showed higher percentages of patients positive for IgG, IgM, and IgA ANAs in the SLE group. Higher IgG/IgM ANA ratios in SLE than DLE show enhanced class-switching and a more sustained humoral response in SLE. They also suggest a potential connection of IgM ANAs with disease containment.
Introduction
Discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE) may or may not coexist, with DLE occurring in 20% of SLE patients [1] and 17% progressing to SLE [2] . Further distinctions have been made between the two diseases through observations of circulating IgG autoantibody levels. Previous studies have shown that IgG antinuclear antibodies (ANAs) are higher in SLE patients versus DLE patients [3, 4] . However, it is unknown whether levels of IgM or IgA ANAs can also be distinguished between DLE and SLE patients. To better understand immunologic relationships between DLE and SLE, we sought to compare the expressions of IgG, IgM, and IgA ANAs in patients with DLE and SLE by enzyme-linked immunosorbent assays (ELISAs) and indirect immunofluorescence (IIF). We hypothesized that the ANA levels for all three isotypes would be the highest in SLE patients, followed by DLE and normal patients.
Materials and Methods

Patients.
Patients were recruited at Outpatient Dermatology and Rheumatology Clinics at the University of Texas Southwestern (UTSW) Medical Center from July 2003 to January 2011. Those giving informed consent to the study were enrolled into either the UTSW Cutaneous Lupus Registry or Dallas Regional Autoimmune Disease Registry. The study was approved by the UTSW Institutional Review Board and was performed according to the ethical standards established by the Declaration of Helsinki. Patients were divided into three age-, gender-, and ethnic-matched groups: SLE, DLE, and normal. SLE patients fulfilled at least four of the American College of Rheumatology (ACR) SLE diagnostic criteria [5] , while DLE patients had a DLE diagnosis based on clinicopathologic correlation and less than four ACR SLE criteria. Normal controls were excluded if they had histories of autoimmune diseases. Demographics, medical history, and clinical data were collected for each patient. In addition, (Figure 1(a) ). Following a similar trend, SLE sera had increased IgM ANA expression (2.76 ± 0.60 OD) compared with DLE (2.36 ± 0.53 OD) and normal (2.04 ± 0.57 OD) sera ( < 0.0001) (Figure 1(b) ). SLE (1.38 ± 1.09 OD) and DLE (0.69 ± 0.64 OD) sera contained higher IgA ANAs compared with normal (0.26 ± 0.21 OD) sera ( < 0.0001) (Figure 1(c) ). None of these isotypes were exclusively elevated in any of these groups. Lastly, SLE sera had the highest ratio of IgG/IgM ANA (59.76 ± 46.64 units/OD) compared with DLE (16.27 ± 11.02 units/OD) and normal (7.18 ± 3.61 units/OD) sera ( < 0.0001) (Figure 1(d) ). (Figure 2(a) ). IgM ANAs were present in 17/32 (53%) SLE, 9/23 (39%) DLE, and 6/22 (27%) normal patients ( = 0.16) (Figure 2(b) ); 12/35 (34%) SLE, 1/23 (4%) DLE, and 4/22 (18%) normal patients exhibited positive IgA ANAs ( = 0.01) (Figure 2(c) ). Most patients from all groups did not have IgG, IgM, or IgA staining against plasma membranes or basement membranes (data not shown).
Results and Discussion
IIF Studies Demonstrated
3.3. Discussion. The ELISA and IIF results indicate that IgG and IgM ANAs are higher in SLE patients compared with DLE and normal patients. Thus, the trend of having greater amounts of circulating ANAs in SLE than DLE applies not only to IgG but also IgM. These differences both reflect the dichotomy between the systemic and skin-limited natures of SLE and DLE, respectively. As one of the ACR SLE diagnostic criteria [5] , IgG ANAs target a variety of nuclear antigens such as double-stranded DNA (dsDNA), which are intimately involved in SLE pathogenesis. IgG antidsDNA antibodies injected into wild-type Balb-c mice and lupus-prone NZBxNZW F1 mice can induce and accelerate nephritis, respectively [6] . These antibodies can form immune complexes in circulation or bind to DNA exposed by glomeruli [7] . Subsequent events including complement activation [8] , production of inflammatory mediators such as cytokines and chemokines, and activation of Fc R on phagocytes ultimately lead to tissue damage [9] . Less is known about IgM ANAs in SLE. Potential antigen targets of these antibodies include single-stranded DNA and dsDNA [10, 11] . Interestingly, IgM anti-dsDNA antibodies negatively correlate with presence of lupus nephritis in SLE patients [12] . Onset of nephritis was also delayed in NZBxNZW F1 mice injected with IgM anti-dsDNA antibodies [13] .
We also found that the ratios of IgG/IgM ANAs were the highest in SLE patients. This implies an amplification of IgM to IgG class-switching and a more robust humoral response in SLE [14] . Moreover, lower IgG/IgM ANA ratios in DLE patients support IgM ANAs being associated with but not necessarily causative of disease containment [15] . Although IgM levels were higher in SLE than DLE patients, the increased ratio of IgG/IgM in SLE patients still hints at a protective effect of IgM. A similar phenomenon has been noted in SLE patients without lupus nephritis. They were found to have lower IgG/IgM ratios of anti-dsDNA antibodies compared with SLE patients with lupus nephritis [16] . It has been postulated that these IgM autoantibodies could decrease IgG autoantibody production by autoreactive B cells, diminish dendritic cell activation, or act as competitive inhibitors with their IgG counterparts by binding to the same circulating nuclear antigens [12, 17, 18] . These mechanisms may be potentially important in preventing systemic spread in DLE patients.
The Scientific World Journal 3 IgA ANAs were elevated in both DLE and SLE patients in the ELISA data. Moreover, IgA was the only immunoglobulin ANA isotype that was differentially expressed between normal and DLE patients. IgA deposits have been detected in the dermal-epidermal junction through direct immunofluorescence in 19/50 (38%) patients with DLE [19] . In MRLlpr mice, which develop cutaneous lupus-like lesions, antidesmoglein 3 IgA correlated with skin disease activity.
Because the rise in anti-desmoglein 3 IgA was associated with mast cell infiltration in skin, it was postulated that antidesmoglein 3 IgA could promote abnormalities in mast cell formation [20] . IgA deposits in skin have also been shown to drive the infiltration of neutrophils in various cutaneous autoimmune diseases such as linear IgA disease [21] . Neutrophils can aggregate in the dermal-epidermal junction in the skin of cutaneous lupus patients [22] . Upon exposure to anti-ribonucleoprotein antibodies, these neutrophils release extracellular traps, which contain dsDNA and other proteins that ultimately stimulate type I interferon production by plasmacytoid dendritic cells [23] . IIF studies on monkey esophagus rather than Hep2 cells were pursued so that we could detect IgG, IgM, and IgA binding against nuclei and other elements of cells in stratified squamous epithelium. Currently, no known antibody of any isotype is distinctly elevated in DLE patients. Desmoglein 3 was previously identified as a tissue-specific antigen in MRLlpr mice [20] . However, DLE and SLE patients showed no significant IgG, IgM, or IgA against plasma and basement membranes, and the ELISA results showed no differences in anti-desmoglein-1 and -3 IgG between the two groups (data not shown).
Limitations include small sample size and selection bias, which was minimized by selecting age-, gender-, and ethnic-matched patients for each group. While IIF findings mostly mirrored the ELISA results, differences are likely due to the decreased sensitivity of detecting ANAs using monkey esophagus as substrate. Future ELISA and indirect immunofluorescence studies with Hep2 cells examining IgG, IgM, and IgA ANAs in a larger population of DLE and SLE patients could be performed to assess their diagnostic significance.
Conclusions
In this study, we have shown the differential expression of IgG, IgM, and IgA ANAs in DLE and SLE patients, providing a global picture of multiple isotypes of ANAs in these lupus subtypes. Decreased IgG/IgM ratios in DLE versus SLE imply amplified IgM to IgG class-switching in SLE and an association of IgM ANAs with prevention of disease spread. Increased IgA ANAs in DLE patients versus normal controls may suggest IgA having some involvement in the etiology of DLE.
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